Redhill Biopharma Ltd.
RDHLStock
$0.73−61.16%52W
Market Cap$4.52M
P/E—
Div yield—
Beta4.99
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-48.55%
Price vs S&P 500 (4W)-6.65%
VGM Score43.19
Market Capitalization$4.52M
Analyst Recommendations
Dec 2024
Jan 2025
Feb 2025
Mar 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RDHLRedhill Biopharma Ltd. | A | F | D | $0.73 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Redhill Biopharma is a specialty biopharmaceutical company focused on gastrointestinal diseases, with commercialized products Talicia and Aemcolo available in the U.S. market. The company maintains a clinical-stage pipeline of five therapeutic candidates, including Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, primarily in clinical development.